Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital

J Pers Med. 2021 May 11;11(5):394. doi: 10.3390/jpm11050394.


Pharmacogenomics (PGx) is a growing field within precision medicine. Testing can help predict adverse events and sub-therapeutic response risks of certain medications. To date, the US FDA lists over 280 drugs which provide biomarker-based dosing guidance for adults and children. At Arkansas Children's Hospital (ACH), a clinical PGx laboratory-based test was developed and implemented to provide guidance on 66 pediatric medications for genotype-guided dosing. This PGx test consists of 174 single nucleotide polymorphisms (SNPs) targeting 23 clinically actionable PGx genes or gene variants. Individual genotypes are processed to provide per-gene discrete results in star-allele and phenotype format. These results are then integrated into EPIC- EHR. Genomic indicators built into EPIC-EHR provide the source for clinical decision support (CDS) for clinicians, providing genotype-guided dosing.

Keywords: best practice alerts (BPAs); clinical decision support (CDS); electronic health records (EHR); genomic indicators; genotype; pediatrics; pharmacogenomics (PGx); phenotype.